High-risk primary breast cancer patients treated with high-dose chemotherapy (HDC) and stem cell support (SCS) have shown prolonged disease-free survival (DFS) in many studies; however, only one trial has demonstrated an overall survival benefit (OS). We hypothesize that the period following myeloablative therapy is ideal for immunologic manipulation and studied the effects of two different methods of immunotherapy following HDC with SCS aimed at the window of immune reconstitution. Seventy-two women with high-risk stage II or III breast cancer were randomized following HDC to receive either interleukin 2 (IL-2) at 1 million units/m 2 SQ daily for 28 days or combined cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to þ 28 and interferon gamma (IFN-c) 0.025 mg/m 2 SQ every 2 days from day þ 7 to þ 28. At a median follow-up of 67 months, no significant difference was observed in DFS or OS between the two treatment groups. The IL-2 arm had a 59% DFS (95% CI (0.45, 0.78)) and a 72% OS (95% CI (0.58, 0.88)) at 5 years. The CsA/INF-c arm had a similar outcome with a 55% DFS (95% CI (0.40, 0.76)) and a 78% OS (95% CI (0.65, 0.94)) at 5 years. Treatment was well tolerated, without increased toxicity.
Introduction
High-dose chemotherapy (HDC) with stem cell support (SCS) for either high-risk primary or advanced breast cancer continues to be a research area for which not all the data are available. While the first-and early secondgeneration randomized transplant trials in the adjuvant settings suggest a benefit in disease-free survival (DFS) in some of the trials, there appears to be no survival benefit in any of the randomized trials except for one. [1] [2] [3] [4] [5] [6] [7] It has been hypothesized that when patients relapse, it is from presumed sub-clinical occult disease and this can be in either the adjuvant or metastatic setting. Many approaches have been employed to tackle the issue of sub-clinical occult disease that includes consolidation at sites of bulk disease (by surgery or radiation), hormonal manipulation and various immunotherapeutic manipulations.
Based on the premise that the immune system must be reeducated to self-following myeloablative therapy, several investigators have identified this window as ideal for immunologic manipulation. First, it is theorized that this minimal residual disease state after intense chemotherapy is ideal for host immune mechanisms to eradicate any tumor cells that may have escaped destruction. Second, since it is presumed that immune recognition must be relearned, exogenous substances may be given to temporarily amplify the immune response by expanding a certain subpopulation of T cells associated with tumor cell kill. In the allogeneic bone marrow transplantation (BMT) setting, graft-versushost disease (GVHD) has been associated with better outcome (presumably due to graft versus tumor (GVT) effect that has not been clearly separated from a GVHD effect), therefore, it has been hypothesized that inducing a parallel situation in autologous BMT might improve the outcome and result in lower relapse rates. 8 Several studies, both preclinical and clinical, have demonstrated that a syndrome similar to GVHD can in fact be induced in the autologous setting by using immunomodulation. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Based on this work, we tested the effect of two methods of immunotherapy following HDC with SCS in high-risk primary breast cancer. We hypothesized that the addition of immunomodulation would improve DFS when compared with historical controls. Patients were randomized to one of two treatment plans: interferon gamma (IFN-g) and cyclosporine A (CsA) or interleukin 2 (IL-2). CsA and IFN-g were combined based on the rationale that IFN-g potentiates CsA-induced GVHD. It has been shown that CsA inhibits thymicdependent clonal deletion, generating CD8 þ autoreactive T cells, which recognize and destroy cells bearing major histocompatibility complex (MHC) class II antigens, whereas, IFN-g acts to upregulate MHC class II expression on cells. Therefore, the net result is an increased tumor cell kill because of increased recognition of the cells themselves. The doses chosen were based on previous phase I results. 19 IL-2 is a major growth factor for T lymphocytes and has been shown to activate the cellular cytotoxicity of natural killer cells against cancer cells (LAK cells) and monocytes. [20] [21] [22] Use of IL-2 in high doses after autologous bone marrow transplantation may activate T-cell reconstitution which has been known to be impaired in this setting. [23] [24] [25] [26] Lower doses of IL-2 have been demonstrated to expand the NK population of lymphocytes with minimal toxicity. The dose of IL-2 used in this study was based on data demonstrating the greatest NK expansion with the least toxicity. 27 
Methods

Patient eligibility
Women between the ages of 18-60 years with high-risk primary breast cancer (American Joint Committee on Cancer (AJCC) stage II X10 involved lymph nodes or stage III). Patients were eligible if hepatic (bilirubin p2 times normal, serum glutamic oxaloacetic transaminase (SGOT) p1.5 times normal), renal (creatinine o1.5 times normal) and cardiac (left ventricular ejection fraction X45%) functions, and performance status (Eastern Cooperative Oncology Group (ECOG) 0-1) were adequate. All patients gave written informed consent. This study was approved by the Institutional Review Board of the Columbia Presbyterian Medical Center.
Treatment
All patients received consolidation therapy consisting of HDC with cyclophosphamide, thiotepa and carboplatin (CTCb) followed by peripheral stem cell infusion according to the dosing schedule shown in Figure 1 .
Immunotherapy and induction of autologous GVHD Following consolidation therapy, patients were treated with radiation and/or tamoxifen if indicated. They were simultaneously randomized to receive one of two immunotherapy regimens including either IL-2 or CsA/INF-g as outlined in Figure 2 . Immune modulators were dosed according to the schedule shown in Figure 3 .
Statistical analysis
Randomization was performed by the Clinical Trials protocol office. Patients were stratified for stage, age, lymph node status and tumor histology. Descriptive statistics are reported as medians. DFS and overall survival (OS) are defined as the time from the discharge from the hospital after CTCb until disease progression or death, respectively, and the curves were estimated by the KaplanMeier product limit method. 28 
Results
Patient characteristics
From June 1997 until November 2001, 72 patients were randomized to HDC followed by IFN-g and CsA or IL-2. A.
B. Patient characteristics are shown in Table 1 . Women enrolled had a median age of 46 years (range 33-64). Thirty-three patients were stage II (46%), 27 stage IIIA (38%), and 12 stage IIIB (inflammatory) (17%). The baseline characteristics of the patients in the two groups were similar with respect to hormone receptor status, type of surgery done at time of diagnosis and type of adjuvant chemotherapy received before HDC. Of the 72 patients enrolled, only two did not complete the immunotherapy regimen.
Adverse events
The most common non-hematologic adverse events related to the two immune therapies were stomatitis/esophagitis, nausea, vomiting and diarrhea (Table 2 ). These events occurred at about the same rate for both treatment regimens. Infection, including bacteremia, urinary tract infection and Clostridium difficile colitis (C. diff), was more commonly observed in the patients who received IL-2 (with only C. diff reaching statistical significance). Cardiac, renal and hepatic toxicities were more prevalent in the group randomized to CsA/IFN treatment. The three cardiac events were mild congestive heart failure that resolved in the post-transplant period. There was one treatment related fatality, which occurred in the CsA/IFN group presumed secondary to the chemotherapy. This toxic death was either due to sepsis or to acute respiratory distress syndrome complicating sepsis.
Survival analysis
The median follow-up of patients was 67 months. There was no significant difference observed in DFS or OS between the two treatment groups (P ¼ NS). The patients treated with IL-2 had a 59% DFS (95% CI (0.45, 0.78)) and a 72% OS (95% CI (0.58, 0.88)) at 5 years. Those patients treated with CsA/INF-g had a similar outcome with a 55% DFS (95% CI (0.40, 0.76)) and a 78% OS (95% CI (0.65, 0.94)) 6,29 at 5 years (see Figure 4) .
Subgroup analysis
When the data were broken down for both tumor histology (non-inflammatory vs inflammatory) and stage (II vs III), there was no significant difference observed in terms of DFS or OS between the two immunomodulatory treatment arms. A post hoc analysis of outcome by HER2-neu status did not alter outcome either. There was a trend toward improved DFS and OS following immunotherapy for patients with inflammatory disease as compared with those patients with stages II and III disease but this finding reflects small numbers of patients.
Discussion
Compared to 10 years ago, when this trial was initially conceived and subsequently conducted, there are many more potential minimal residual strategies available secondary to many advances pioneered in cancer biology. Nevertheless, immune modulation remains one of the most attractive targets to potentially sustain a response against cancer cells -occult and overt. Deriving from observations that patients with leukemia who develop even a small amount of GVHD fare better, many investigators attempted to replicate this in the autotransplant setting. In addition, other investigators piloted varying schedules of (IL-2) with some encouraging results. 22, 27, 30 Studies of allogeneic stem cell transplant in solid tumors further support the concept that an anticancer effect is observed with the withdrawal of immunosuppression. This study attempted to compare two very different approaches to immune modulation in an effort to elicit whether any difference in toxicity profile or efficacy existed in this population. Our study suggests that there is no difference between the two arms in terms of DFS or OS with 6 years of follow-up. Furthermore, when compared the high-dose arms of the phase III trials (see Table 3 ) without any immune manipulation, the results are very similar. In general, both the IL-2 and CsA/IFN-g were well tolerated, with evidence of skin changes consistent with GVHD developing in only one of eight patients undergoing a skin biopsy in the CsA/IFN-g arm (data not shown).
Unlike the previous studies that examined immune modulation following HDC and autologous SCS, our study has the advantage of 6 years of follow-up. However, despite this time frame, no significant difference was observed in either DFS or OS with either immunotherapeutic regimen. Of course improvements in outcome from HDC in this population might be seen later and a metaanalysis recently presented by the Early Breast Cancer Trialists Group will further explore this concept. The relatively small sample population studied could have biased the results toward the null hypothesis, and perhaps with larger numbers a significant benefit would have been found. Furthermore, the design of the study did not allow for a comparison between an immunomodulatory approach following HDC to HDC alone. Therefore, the efficacy of these immune therapies can only be evaluated with respect to one another. Finally, the dose and length of treatment with each immune modulator may not have been optimal, (as evidenced by only a small percentage of patients exhibiting skin changes consistent with GVHD therefore, unable to produce significant effect).
Today, minimal residual disease strategies have taken a different turn and antiangiogenesis and dendritic cell biology strategies are at the forefront of research. Many groups have reported the induction of an antitumor immune response using a combination of apoptosisinducing treatment of tumors (i.e. chemotherapy or radiation) with concurrent administration of dendritic cells. 31, 32 A number of studies have found that vaccination with dendritic cell-breast cancer fusions induces antitumor immunity and clinical response in patients with metastatic breast cancer. 33, 34 More provocative and most similar in design to our study is a report by Chui et al. 35 that examined the efficacy of tumor antigen-loaded dendritic cell immunotherapy following treatment with HDC and autologous stem-cell support in patients with high-risk and advanced breast cancer. They found that the dendritic cell vaccination had a low side-effect profile and was effective in halting disease progression with 4 out of 9 patients treated with no evidence of disease (range 331-1141 days).
In addition to dendritic cell vaccines, there are numerous other strategies being explored to modulate the immune system in breast cancer to eradicate occult disease. Two interesting methods include cellular based and allogeneic immunotherapy. Adoptive infusion of tumor-reactive T cells is aimed at harnessing the autologous immune system to infiltrate, proliferate and kill tumor cells. Early clinical studies in metastatic breast cancer show some efficacy of this strategy. 36, 37 Others have explored using HDC followed by autologous transplantation to first cyto-reduce disease, and then employing allogenic transplantation to optimize GVT effect. 38, 39 The concept of inhibiting tumor angiogenesis as a method of cancer treatment and/or prevention was originally proposed over 30 years ago; however, it is not until recently that we have had the development of effective in vivo antiangiogenic strategies allowing for translational medicine. 40, 41 While bevacuzimab, an antiangiogenic monoclonal antibody against vascular endothelial growth factor A (VEGF-A), has activity in advanced breast cancer, there are several other antiangiogenic molecules in development. 42 One of the more novel approaches is the use of tetrahiomolybdate (TM), a copper chelator, which is thought to work by indirectly inhibiting multiple activators of angiogenesis including nuclear factor kB. 29, 43 A group at Cornell is currently conducting a phase II clinical trial examining the efficacy of TM in patients with breast cancer at moderate to high risk of recurrence after completion of standard therapy. The rationale being that the angiogenic switch can be kept in the 'off' position indefinitely; yet another minimal residual disease approach to ultimately increase the proportion of cured patients with breast cancer.
Conclusion
Immunotherapy with either IL-2 or CsA/INF-g following HDC with SCS in women with high-risk primary breast cancer did not have a significant effect on DFS or OS. Furthermore, these data are similar when compared with DFS/OS of HDC for patients with high-risk primary breast cancer who have not received immunomodulation. While the observation that outcome might be better in patients with inflammatory breast cancer is provocative, the numbers in this study are too small to draw any firm conclusions. Certainly, an immunomodulatory approach with CsA and IFN-g following standard dose chemotherapy in this population might be warranted, as most of the vaccine trials have been disappointing in breast cancer. In addition, there may only be an as yet unidentified subtype of breast cancer that benefits from this strategy. Genomics will undoubtedly contribute to the understanding of this in the future. Ongoing research in understanding the concept of tumor dormancy and in developing effective minimal residual disease strategies will be critical to continue to improve survival of patients with breast and other cancers.
